Programmable recombinase technology represents a transformative advancement in the field of gene editing, offering unprecedented precision and versatility for genomic modifications. Unlike traditional approaches, which often rely on CRISPR-based systems, other nuclease-dependent methodologies and cellular DNA repair, programmable recombinases achieve targeted DNA edits without inducing double-strand breaks or relying on cellular DNA repair mechanisms. This unique capability might lower the risk of off-target effects and enhance the fidelity of genetic modifications.

Programmable recombinases allow for precise insertion, deletion, and replacement of large DNA sequences at predetermined genomic loci, thereby expanding their applicability across a broad spectrum of therapeutic areas. From correcting pathogenic mutations in monogenic diseases to engineering complex genomic rearrangements, our platform addresses key challenges in developing durable and effective gene therapies.

We will share some of our initial data on programmable Large Serine Recombinases (LSRs) for targeted integration of DNA to potentially allow for treatment of multiple diseases, and our approach to use large deletions to treat blood disorders. Our platform research is focused on optimising recombinase engineering to further enhance their specificity and programmability, with the goal of translating these innovations into clinical therapeutics.